Repatha Archives -

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for

Verve starts trials of cholesterol drug in test of base editing technique

https://pharmaphorum.com/news/verve-starts-trials-of-cholesterol-drug-in-test-of-base-editing-technique/

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce

Novartis bags elusive US approval for cholesterol drug inclisiran

https://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t

Amgen pulls higher-priced Repatha to try to lift sales

https://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?

https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/

Amgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but

Cancer update buoys Amgen despite Q2 sales fall

https://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic

Praluent approved to reduce CV risk in Europe

https://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/

Repatha